Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
McKinsey
Harvard Business School
Baxter

Last Updated: June 29, 2022

Alemtuzumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for alemtuzumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Neovii BiotechPhase 2
Clinical Trial Center North (CTC North GmbH & Co. KG)Phase 2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)N/A

See all alemtuzumab clinical trials

Recent Litigation for alemtuzumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AMGEN INC. v. APOTEX INC.2022-06-14
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11

See all alemtuzumab litigation

PTAB Litigation
PetitionerDate
Miltenyi Biomedicine GmbH2022-04-12
GEMoaB Monoclonals GmbH2019-12-20
Forty Seven, Inc.2018-01-08

See all alemtuzumab litigation

Pharmacology for alemtuzumab
Mechanism of ActionCD52-directed Antibody Interactions
Established Pharmacologic ClassCD52-directed Cytolytic Antibody
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for alemtuzumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for alemtuzumab Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2013-08-13 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2013-08-13 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2014-08-05 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2015-12-08 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2013-12-28 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2020-05-27 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for alemtuzumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for alemtuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016/024 Ireland See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130912
C 2016 020 Romania See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/13/869; DATE OF NATIONAL AUTHORISATION: 20130912; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/869; DATE OF FIRST AUTHORISATION IN EEA: 20130912
132016000055697 Italy See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916
132008901655481 Italy See Plans and Pricing PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531
SZ 32/2001 Austria See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB
253 5012-2016 Slovakia See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Harvard Business School
Merck
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.